Stay updated on Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Fallopian tube cancer term added and a link to the Genetic and Rare Diseases Information Center added under resources. Page revision updated from v3.4.1 to v3.4.2.
    Difference
    0.2%
    Check dated 2026-02-13T12:47:45.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The page now displays a revision update from v3.4.0 to v3.4.1, which is a minor change that does not modify the study details or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-06T09:18:00.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    The changes are minor UI and versioning updates: addition of Show glossary and Hide glossary options, and label wording updates (Last Update Submitted that Met QC Criteria, No FEAR Act Data) plus the revision tag to v3.4.0. These updates do not modify the study content or how the page functions.
    Difference
    0.4%
    Check dated 2026-01-22T17:43:51.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and Revision: v3.3.3 was removed, which are metadata updates that do not alter the study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T10:55:42.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    Revision: v3.3.3 is now displayed in the footer, and the older Revision: v3.3.2 label has been removed along with the HHS Vulnerability Disclosure link. These changes affect only footer metadata and branding and do not modify the study content or functionality.
    Difference
    0.1%
    Check dated 2025-12-17T20:30:43.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    - Revision: v3.3.2 added and v3.2.0 removed. This is a minor metadata update at the bottom of the page and does not affect the study information.
    Difference
    0.1%
    Check dated 2025-11-26T08:31:36.000Z thumbnail image

Stay in the know with updates to Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.